Oncosyne’s CTO, Peter W. Eide, presented recent advances from the INVICTA pancreatic cancer project at the 2026 NOR-MPS Symposium – the annual Nordic Organoid and Microphysiological Systems Convention held in Oslo.
In his flash talk, Peter highlighted significant progress in the INVICTA collaboration between Sahlgrenska University Hospital, Hybrid Technology Hub (HTH), Institute for Molecular Medicine Finland (FIMM), and Oncosyne. The presentation demonstrated how coordinated clinical and technological development is enabling patient-relevant modeling in pancreatic ductal adenocarcinoma (PDAC).
Key milestones presented included:
- Establishment of efficient clinical logistics for rapid processing of patient material
- Development of a clinically relevant PDAC biobank
- State-of-the-art organoid establishment success rates
- Implementation of clinical-grade functional assays for high-content drug screening
- Iterative development of organ-on-chip systems incorporating co-culture modules, further expanding Oncosyne’s technology platform
Following the presentation, Peter participated in the panel discussion titled “Collaborate to Accelerate: Developers and End-Users Driving Organ-on-Chip Innovation.” The debate focused on how partnerships between start-ups, pharmaceutical companies, and infrastructure partners can effectively start, scale, and succeed. Discussions emphasized the importance of aligning incentives, establishing early scientific dialogue, and building long-term collaborative frameworks to accelerate translational impact.
The panel also highlighted the Nordics as a growing hub for organoid and microphysiological systems (MPS) innovation, where strong academic environments, clinical integration, and collaborative ecosystems create favorable conditions for advancing patient-derived modeling technologies.
We thank the organizers and fellow panelists for an engaging and forward-looking symposium and look forward to continuing the collaborative efforts required to bring more predictive, patient-relevant models into drug development and healthcare.
